Skip to main content
. 2021 Mar 9;13(5):1179. doi: 10.3390/cancers13051179

Figure 6.

Figure 6

Drug screening of cancer organoid and validation of clinical case. (A,B) Magnetic resonance images of patient 8 at admission (A) and after receiving treatment of gemcitabine plus albumin-bound paclitaxel for three months (B). (CF) Dose-response curves and half-maximal inhibitory concentrations (IC50) of the derived IHCC organoid treated with conventional chemotherapeutic drugs (C,D) and targeted drugs (E,F). Screening of each drug was performed in triplicate.